Drug intelligence / Profile preview

meglumine gamma-linolenic acid

Development stage: Unknown
Modality: Small Molecules
Administration: Intra-arterial

Overview

MeGLA is an investigational aqueous salt formulation of gamma-linolenic acid with meglumine, developed for local intravesical administration in recurrent superficial bladder cancer. Gamma-linolenic acid is an omega-6 polyunsaturated fatty acid; MeGLA showed direct cytostatic and cytotoxic activity in cancer-cell models, although a discrete molecular target has not been established. In a Phase II study in recurrent superficial transitional-cell bladder cancer, a single intravesical instillation was tolerated and produced complete or partial tumor responses in some participants. MeGLA also inhibited growth of pancreatic cancer cell lines in vitro. ([europeanurology.com](https://www.europeanurology.com/article/S0302-2838%2802%2900208-7/fulltext))

Other names: MeGLA

Beyond the preview

Go deeper on meglumine gamma-linolenic acid.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on meglumine gamma-linolenic acid.

Explore the full profile